OPEN ACCESS Freely available online

Immunological Disorders & Immunotherapy

Short Communication

Mitochondrial Dysfunction: A New Therapeutic Target for Sepsis-Associated Kidney Injury

Jaxith Krell*

Department of Immunology, McGill University, Montreal, Canada

DESCRIPTION

Sepsis is the most extreme expression of immunological chaos a "systemic storm" that can lead to organ failure within hours. In 2025, the most significant breakthrough in critical care immunology is the recognition that sepsis-induced kidney failure is not just caused by "low blood pressure" or "inflammation," but by a "power failure" at the cellular level. The "root" of organ failure in sepsis is "mitochondrial arrest." When the immune system over-responds to an infection, it inadvertently "paralyzes" the power plants of the kidneys.

This shift in focus from "hemodynamics" (blood flow) to "bioenergetics" (cell energy) has opened the door to revolutionary remedies. We are no longer just trying to "keep the patient alive"; we are trying to "re-start the engines" of their vital organs.

The biological roots of Sepsis-Associated Kidney Injury (AKI) lie in the "nitric oxide overload." During sepsis, the immune system produces massive amounts of nitric oxide to kill bacteria. However, nitric oxide also binds to the enzymes in the mitochondria, the organelles responsible for producing energy molecules. The kidneys are among the most energy-hungry organs in the body; when their mitochondria are poisoned by nitric oxide, they can no longer perform the work of filtering blood.

Instead of dying, the kidney cells enter a state of "metabolic paralysis" or "hibernation." They shut down all non-essential functions to conserve energy, hoping to survive the inflammatory storm. This "root" cause explains why patients often suffer from kidney failure even when their blood pressure is stabilized the cells are physically unable to "turn back on." By 2025, we have identified "mitochondrial fragmentomic markers" leaking into the blood as a key biomarker for this crisis. This is a "call for help" from the cells, indicating that the immune system's over-aggressive defense has led to an internal energy collapse. This understanding changes the "lived experience" of the hospital where the focus shifts from the monitor to the molecule.

Mitochondrial resuscitation and NAD+ boosters

The remedy in 2025 is "mitochondrial resuscitation." This involves the administration of "mito-protective" agents that can displace nitric oxide from the mitochondrial enzymes, allowing the kidney cells to breathe again. Additionally, clinicians are Using high-dose intravenous precursors is clinically essential for molecules for energy production to "jump-start" the energy cycle the kidneys. This is like jump-starting a car battery during a blizzard; it provides the energy needed for the organ to resume its filtering duties.

Clinical precision is achieved through "real-time metabolic monitoring." In 2025, hospital physicians use bedside sensors to track the oxygen consumption of the patient's cells. If the sensors show a "power drop," the mitochondrial remedies are titrated immediately. This approach has drastically reduced the need for long-term dialysis in sepsis survivors. By treating the "root" energy crisis rather than just the "symptom" of low urine output, we are providing a much more effective remedy for the body's most critical emergencies. This is the future of "critical care immunology" protecting the cell's life force amidst the chaos of systemic inflammation.

The evolution of sepsis treatment in 2025 marks the end of the "hemodynamic era" and the beginning of advanced metabolic resuscitation. For decades, medicine viewed sepsis as a purely plumbing problem, assuming that if we could just push enough blood through the kidneys, they would function. However, the discovery of mitochondrial arrest has revealed that the kidneys are not "starving" for blood; they are effectively "paralyzed" by the very nitric oxide the immune system uses for defense. By shifting the clinical focus from blood pressure to the bioenergetic state of the cell, 2025 clinicians can now intervene before the cellular "hibernation" becomes permanent, using mitochondrial DNA fragments as a high-tech smoke alarm for organ failure.

CONCLUSION

The recognition of mitochondrial dysfunction as the root of sepsis-associated organ failure is a paradigm shift in emergency

Correspondence to: Jaxith Krell, Department of Immunology, McGill University, Montreal, Canada, Email: krell@gmail.com

Received:20-Aug-2025, Manuscript No. IDIT-25-41653; **Editor assigned:** 22-Aug-2025, PreQC No. IDIT-25-41653 (PQ);**Reviewed:** 07-Sep-2025, QC No. IDIT-25-41653; **Revised:**14-Sep-2025, Manuscript No.IDIT-26-41653 (R);**Published:** 21-Sep-2025, DOI: 10.35248/2593-8509.25.10.228

Citation: Krell J (2025). Mitochondrial Dysfunction: A New Therapeutic Target for Sepsis-Associated Kidney Injury. Immunol Disord Immunother. 10:228.

medicine. By applying remedies that focus on "mitochondrial resuscitation," we are moving beyond supportive care toward active cellular repair. This ensures that the survivors of sepsis do not just survive the infection, but emerge with their vital organs and their future health fully intact.

REFERENCES

1. Manrique-Caballero CL, Del Rio-Pertuz G, Gomez H. Sepsis-associated acute kidney injury. Crit Care Clin. 2021;37(2):279-301.
2. Creagh-Brown BC, Griffiths MJD, Evans TW. Bench-to-bedside review: Inhaled nitric oxide therapy in adults. Crit Care. 2009;13(3):221.
3. He FF, Wang YM, Chen YY, Huang W, Li ZQ, Zhang C, et al. Sepsis-induced AKI: From pathogenesis to therapeutic approaches. Front Pharmacol. 2022;13:981578.
4. Galley HF. Oxidative stress and mitochondrial dysfunction in sepsis. Br J Anaesth. 2011;107(1):57-64.
5. Singer M. The role of mitochondrial dysfunction in sepsis-induced multi-organ failure. Virulence. 2014;5(1):66-72.
6. Pool R, Gomez H, Kellum JA. Mechanisms of organ dysfunction in sepsis. Crit Care Clin. 2018;34(1):63-80.
7. Dare AJ, Phillips AR, Hickey AJ, Mittal A, Loveday B, Thompson N, et al. A systematic review of experimental treatments for mitochondrial dysfunction in sepsis and multiple organ dysfunction syndrome. Free Radic Biol Med. 2009;47(11): 1517-1525.
8. Sureshbabu A, Patino E, Ma KC, Laursen K, Finkelsztein E J, Akchurin O, et al. RIPK3 promotes sepsis-induced acute kidney injury mitochondrial dysfunction. JCI Insight. 2018;3(11), e98411.
9. Kumar V. Sepsis roadmap: what we know, what we learned, and where we are going. Clin Immunol. 2020;210:108264.
10. Nakahira K, Kyung SY, Rogers AJ, Gazourian L, Youn S, Massaro AF, et al. Circulating mitochondrial DNA in patients in the ICU as a marker of mortality: Derivation and validation. PLoS Med. 2013;10(12):e1001577.